Phenylpropanolamine

Summary

Phenylpropanolamine (CHEMBL61006) is an approved small molecule (ATC R01BA01); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R01BA01 (+1 more)
• Indications: 1 condition
• Chemistry: 151.21 Da · C9H13NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL61006
Name	Phenylpropanolamine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4786
ATC	R01BA01, R01BA51
Molecular formula	C9H13NO
Molecular weight	151.21
InChIKey	DLNKOYKMWOXYQA-UHFFFAOYSA-N

SMILES: CC(C(C1=CC=CC=C1)O)N

IUPAC name: 2-amino-1-phenylpropan-1-ol

Also known as: Fansia, Fenilpropanolamina, Norephedrine, NSC-9920, Phenylfenesin, Phenylpropanolamine, Propadrine, Rinexin, (-)-Norephedrine, PHENYLPROPANOLAMINE, phenylpropanolamine

Parent form; salt/anhydrous children: CHEMBL1200695, CHEMBL1201535, CHEMBL2146104

Patent coverage: 1,562 distinct patent families (5,555 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1A adrenergic receptor, Alpha-1D adrenergic receptor.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 10 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P19328	6.58	Ki	263	nM	CHEMBL_ACT_434867
ADRA2A	6.56	Ki	275.4	nM	CHEMBL_ACT_434866
ADRA2C	5.14	AC50	7300	nM	CHEMBL_ACT_25147820
P23944	5.07	Ki	8511	nM	CHEMBL_ACT_12459247
P23944	5.07	Ki	8511	nM	CHEMBL_ACT_434855
P18841	5.02	Ki	9550	nM	CHEMBL_ACT_12459277
P18841	5.02	Ki	9550	nM	CHEMBL_ACT_434854
P43140	5.01	Ki	9772	nM	CHEMBL_ACT_12459307
P43140	5.01	Ki	9772	nM	CHEMBL_ACT_434853

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).